Literature DB >> 20963505

Is left ventricular dysfunction reversed after treatment of active acromegaly?

Savvas T H Toumanidis1, Maria Eleftheria Evangelopoulos, Ioannis Ilias, Constantinos Pamboucas, Chrysanthi Trikka, Maria Alevizaki.   

Abstract

It has been suggested that control of GH and IGF excess can arrest the progression of cardiovascular abnormalities and normalize cardiac performance. The aim of the present study was to investigate the reversibility of acromegalic cardiomyopathy in patients with active and inactive disease and to evaluate the effect of the inactivity of the disease on left ventricular (LV) diastolic dysfunction, irrespective of the applied treatment. The patient population consisted of 55 patients who were studied in the active and/or inactive phase. A complete M-mode, two-dimensional and color-flow Doppler echocardiographic examination was performed. LV mass index and posterior wall index were significantly lower in patients with inactive acromegaly compared to those with active disease (P < 0.03 respectively). Diastolic dysfunction was improved in patients with inactive compared to those with active disease (E/A ratio P < 0.009). IGF was positively correlated with LV mass index (r = 0.28, P < 0.02). Multivariate linear regression analysis showed that in active patients the E/A ratio was independently related to age (β = -0.674, P < 0.001) and GH (β = 0.282, P < 0.03), whereas in inactive patients none of the parameters were related significantly with the E/A ratio. In a subgroup of 15 patients who were studied in both the active and inactive phase of the disease, the reduction in GH levels was correlated positively with the reduction in LV mass index (r = 0.89, P < 0.0001) and negatively with the improvement in E/A ratio (r = -0.74, P < 0.001). In conclusion, the results of the present study indicate an improvement of left ventricular diastolic function and a significant improvement of cardiac hypertrophy in patients with inactive acromegaly and normal systolic cardiac function compared to those with active disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20963505     DOI: 10.1007/s11102-010-0263-2

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  21 in total

Review 1.  Cardiovascular function in acromegaly.

Authors:  R N Clayton
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

2.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

Authors:  R B Devereux; D R Alonso; E M Lutas; G J Gottlieb; E Campo; I Sachs; N Reichek
Journal:  Am J Cardiol       Date:  1986-02-15       Impact factor: 2.778

3.  Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.

Authors:  D J Sahn; A DeMaria; J Kisslo; A Weyman
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

Review 4.  Insulin-like growth factor I and its binding proteins in the cardiovascular system.

Authors:  P Delafontaine
Journal:  Cardiovasc Res       Date:  1995-12       Impact factor: 10.787

5.  Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide.

Authors:  Annamaria Colao; Paolo Marzullo; Alberto Cuocolo; Letizia Spinelli; Rosario Pivonello; Domenico Bonaduce; Marco Salvatore; Gaetano Lombardi
Journal:  Clin Endocrinol (Oxf)       Date:  2003-02       Impact factor: 3.478

6.  Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance.

Authors:  Rosario Pivonello; Maurizio Galderisi; Renata S Auriemma; Maria Cristina De Martino; Mariano Galdiero; Antonio Ciccarelli; Arcangelo D'Errico; Ione Kourides; Pia Burman; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2006-11-14       Impact factor: 5.958

7.  The cardiovascular effects of octreotide treatment in acromegaly: an echocardiographic study.

Authors:  L Thuesen; S E Christensen; J Weeke; H Orskov; P Henningsen
Journal:  Clin Endocrinol (Oxf)       Date:  1989-06       Impact factor: 3.478

8.  Diastolic function study with conventional and pulsed tissue Doppler echocardiography imaging in acromegalic patients.

Authors:  Carolina G S Leães; Caroline K Kramer; Julia F S Pereira-Lima; Domingos M Hatem; Iran Castro; Miriam da C Oliveira
Journal:  Echocardiography       Date:  2009-04-08       Impact factor: 1.724

9.  Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.

Authors:  B Merola; A Cittadini; A Colao; D Ferone; S Fazio; D Sabatini; B Biondi; L Saccá; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

10.  Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.

Authors:  Shlomo Melmed; David Cook; Jochen Schopohl; Miklos I Goth; Karen S L Lam; Josef Marek
Journal:  Pituitary       Date:  2009-07-29       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.